Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 27, 2016Future Oncology

Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia

View Full Paper
Ask AI
Bookmark
Share

Authors

EWElliott F. WintonVKVamsi Kota

Discussion

Loading...

Member takes

Overview

Clinical trial analysis demonstrates reduced anemia with momelotinib in myelofibrosis, indicating potential therapeutic utility beyond standard JAK2 inhibition.

Key Points

  • To review the therapeutic potential and anemia-reducing effects of the JAK1/2 inhibitor momelotinib in myelofibrosis.
  • Reviewed outcomes from Phase I/II clinical trials evaluating momelotinib in patients diagnosed with myelofibrosis.
  • Assessed changes in constitutional symptoms, spleen size, and red blood cell parameters during treatment.
  • Phase I/II clinical trials demonstrated unexpected alleviation and reduction of anemia in patients treated with momelotinib.
  • Momelotinib treatment simultaneously suppressed inflammatory symptoms and splenomegaly driven by aberrant JAK2/STAT signaling.

Cite This Study

Winton et al. (2016) studied this question.

synapsesocial.com/papers/6a1ab56f49c3147e1045e1eehttps://doi.org/10.2217/fon-2016-0417
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study2025 · 2 citations
  2. 2Momelotinib – a promising advancement in the management of myelofibrosis in adults with anemia2024 · 4 citations
  3. 3Efficacy and Safety of Momelotinib in Myelofibrosis: A Systematic Review and Meta-Analysis With a Focus on Anemia Outcomes.2025 · 2 citations
  4. 4Momelotinib's unique polypharmacology supports indication expansion beyond myelofibrosis2025
  5. 5Discovery of drug combinations with momelotinib to improve myelofibrosis outcomes2025